X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs AUROBINDO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB AUROBINDO PHARMA DR. REDDYS LAB/
AUROBINDO PHARMA
 
P/E (TTM) x 22.2 15.3 145.3% View Chart
P/BV x 3.4 3.1 109.4% View Chart
Dividend Yield % 0.8 0.4 192.4%  

Financials

 DR. REDDYS LAB   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
AUROBINDO PHARMA
Mar-18
DR. REDDYS LAB/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788809 344.6%   
Low Rs1,902504 377.3%   
Sales per share (Unadj.) Rs860.8281.1 306.3%  
Earnings per share (Unadj.) Rs57.141.4 138.0%  
Cash flow per share (Unadj.) Rs122.050.9 239.8%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %0.90.4 224.0%  
Book value per share (Unadj.) Rs757.7199.4 380.1%  
Shares outstanding (eoy) m165.91585.88 28.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.3 116.6%   
Avg P/E ratio x41.115.9 258.8%  
P/CF ratio (eoy) x19.212.9 149.0%  
Price / Book Value ratio x3.13.3 94.0%  
Dividend payout %35.06.0 579.7%   
Avg Mkt Cap Rs m389,034384,630 101.1%   
No. of employees `00023.517.3 135.7%   
Total wages/salary Rs m32,14921,308 150.9%   
Avg. sales/employee Rs Th6,070.89,500.7 63.9%   
Avg. wages/employee Rs Th1,366.61,229.4 111.2%   
Avg. net profit/employee Rs Th402.51,397.9 28.8%   
INCOME DATA
Net Sales Rs m142,810164,666 86.7%  
Other income Rs m1,5521,020 152.2%   
Total revenues Rs m144,362165,686 87.1%   
Gross profit Rs m23,51237,718 62.3%  
Depreciation Rs m10,7725,580 193.1%   
Interest Rs m788777 101.4%   
Profit before tax Rs m13,50432,380 41.7%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3808,183 53.5%   
Profit after tax Rs m9,46824,229 39.1%  
Gross profit margin %16.522.9 71.9%  
Effective tax rate %32.425.3 128.4%   
Net profit margin %6.614.7 45.1%  
BALANCE SHEET DATA
Current assets Rs m104,984121,878 86.1%   
Current liabilities Rs m68,93886,806 79.4%   
Net working cap to sales %25.221.3 118.5%  
Current ratio x1.51.4 108.5%  
Inventory Days Days74130 57.3%  
Debtors Days Days10468 151.5%  
Net fixed assets Rs m104,38581,037 128.8%   
Share capital Rs m830586 141.7%   
"Free" reserves Rs m124,886116,218 107.5%   
Net worth Rs m125,716116,804 107.6%   
Long term debt Rs m25,0894,512 556.1%   
Total assets Rs m225,443211,052 106.8%  
Interest coverage x18.142.7 42.5%   
Debt to equity ratio x0.20 516.6%  
Sales to assets ratio x0.60.8 81.2%   
Return on assets %4.511.8 38.4%  
Return on equity %7.520.7 36.3%  
Return on capital %9.727.4 35.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62380,727 90.0%   
Fx outflow Rs m18,91634,700 54.5%   
Net fx Rs m53,70746,027 116.7%   
CASH FLOW
From Operations Rs m18,03019,548 92.2%  
From Investments Rs m-14,883-19,570 76.1%  
From Financial Activity Rs m-4,4408,642 -51.4%  
Net Cashflow Rs m-1,2368,922 -13.9%  

Share Holding

Indian Promoters % 25.5 54.1 47.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.0 67.9%  
FIIs % 35.3 27.7 127.4%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.2 150.0%  
Shareholders   75,885 69,601 109.0%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Jet Airways and Yes Bank - What's Next for these Beaten Down Stocks?(Podcast)

Jet Airways and Yes Bank, both once market darlings are now being shunned by market participants. The National Stock Exchange (NSE) exchange notified that the shares of the airline.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 14, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS